590 reports of this reaction
1.2% of all IMATINIB MESYLATE reports
#20 most reported adverse reaction
OEDEMA PERIPHERAL is the #20 most commonly reported adverse reaction for IMATINIB MESYLATE, manufactured by Novartis Pharmaceuticals Corporation. There are 590 FDA adverse event reports linking IMATINIB MESYLATE to OEDEMA PERIPHERAL. This represents approximately 1.2% of all 47,520 adverse event reports for this drug.
Patients taking IMATINIB MESYLATE who experience oedema peripheral should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OEDEMA PERIPHERAL is a less commonly reported adverse event for IMATINIB MESYLATE, but still significant enough to appear in the safety profile.
In addition to oedema peripheral, the following adverse reactions have been reported for IMATINIB MESYLATE:
The following drugs have also been linked to oedema peripheral in FDA adverse event reports:
OEDEMA PERIPHERAL has been reported as an adverse event in 590 FDA reports for IMATINIB MESYLATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
OEDEMA PERIPHERAL accounts for approximately 1.2% of all adverse event reports for IMATINIB MESYLATE, making it a notable side effect.
If you experience oedema peripheral while taking IMATINIB MESYLATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.